Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.
You may also be interested in...
Zicam Maker Matrixx Settles With Shareholders Over H.I.G. Buyout
Matrixx Initiatives remains mired in multiple lawsuits despite settling litigation with shareholders over the firm’s handling of its 2010 buyout.
FDA Warns Matrixx On Combination Supplement/Drug Products
Matrixx Initiatives’ troubled history with FDA continues with a warning two of its products are unapproved new drugs because they combine supplements with OTC drugs.
Matrixx Sales Drop Nearly 30% In Final Quarter Before Buyout
Matrixx Initiatives posts an $11.3 million net loss in what is likely its last quarter as a publicly traded company before its acquisition by private equity firm H.I.G. Capital.